JAZZ
Research Snapshot
Static fundamentals, valuation context, and investor signals for Jazz Pharmaceuticals plc (JAZZ).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-3.7%
ROIC, 30.4% FCF margin
Growth
12.5%
5Y sales (revenue) CAGR
Balance sheet
1.2x
Debt/equity, 1.9x current ratio
Superinvestors
1
Top: Tweedy Browne Co. (0.9%)
Strengths to research
- Revenue compounded at 12.5% over five years.
- Free cash flow margin is healthy at 30.4%.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for JAZZ.
Grade D
42
/ 100
Financial Charts
No financial data available for JAZZ (annual).
1 superinvestors own JAZZ
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Tweedy Browne Co. Tweedy Browne Value Fund | 60,209 | $11M | 0.90% | 0.0% |